



Impact of dietary carbohydrate, fat or protein restriction on the human gut microbiome: a systematic review

Marjolein P. Schoonakker^{1*} , Petra G. van Peet¹, Elske L. van den Burg¹, Mattijs E. Numans¹, Quinten R. Ducarmon², Hanno Pijl^{1,3} and Maria Wiese^{2,4}

¹Department of Public Health and Primary Care, Leiden University Medical Centre (LUMC), Leiden, The Netherlands

²Department of Medical Microbiology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands

³Department of Internal Medicine, Leiden University Medical Centre (LUMC), Leiden, The Netherlands

⁴Microbiology and Systems Biology, The Netherlands Organization for Applied Scientific Research (TNO), Leiden, The Netherlands

Abstract

Restriction of dietary carbohydrates, fat and/or protein is often used to reduce body weight and/or treat (metabolic) diseases. Since diet is a key modulator of the human gut microbiome, which plays an important role in health and disease, this review aims to provide an overview of current knowledge of the effects of macronutrient-restricted diets on gut microbial composition and metabolites. A structured search strategy was performed in several databases. After screening for inclusion and exclusion criteria, thirty-six articles could be included. Data are included in the results only when supported by at least three independent studies to enhance the reliability of our conclusions. Low-carbohydrate (<30 energy%) diets tended to induce a decrease in the relative abundance of several health-promoting bacteria, including *Bifidobacterium*, as well as a reduction in short-chain fatty acid (SCFA) levels in faeces. In contrast, low-fat diets (<30 energy%) increased alpha diversity, faecal SCFA levels and abundance of some beneficial bacteria, including *Faecalibacterium prausnitzii*. There were insufficient data to draw conclusions concerning the effects of low-protein (<10 energy%) diets on gut microbiota. Although the data of included studies unveil possible benefits of low-fat and potential drawbacks of low-carbohydrate diets for human gut microbiota, the diversity in study designs made it difficult to draw firm conclusions. Using a more uniform methodology in design, sample processing and sharing raw sequence data could foster our understanding of the effects of macronutrient restriction on gut microbiota composition and metabolic dynamics relevant to health. This systematic review was registered at <https://www.crd.york.ac.uk/prospero> as CRD42020156929.

Key words: diet: dietary carbohydrates: dietary fats: dietary proteins: gastrointestinal tract: gut microbiota: short-chain fatty acids: systematic review

(Received 23 February 2023; revised 3 March 2024; accepted 3 April 2024; accepted manuscript published online 11 April 2024)

Introduction

A wide range of diets has been developed over the past decades to reduce weight and/or to improve health^(1–7). Reducing the amount of any of the macronutrients, fat, carbohydrate or protein, is often used as a dietary strategy^(1,2,4,8). Such dietary alterations have been applied for the treatment of several diseases, including type 2 diabetes (T2D)^(9–11), chronic kidney disease^(12–15), epilepsy^(16–18) and inflammatory bowel disease^(19–21). It has been suggested that an important effect of diet on health is mediated via the gut microbiome⁽²²⁾, and evidence is emerging that microbial metabolites may affect health by acting as signalling molecules⁽²³⁾. The gut microbiome, also referred to as the forgotten organ⁽²⁴⁾, is an essential component of the human body. The human digestive tract harbours a diverse community of primarily anaerobic micro-organisms. The conditions, as well as the numbers of bacteria differ considerably in the various sections of the gastrointestinal

tract, which hosts up to 10^3 colony-forming units (cfu) per millilitre (cfu ml⁻¹) in the stomach and duodenum, while the numbers increase in jejunum and ileum (10^4 – 10^8 cfu ml⁻¹) and rise to even higher levels in the colon (10^9 – 10^{12} cfu ml⁻¹)⁽²⁵⁾. Hundreds of different bacterial species can be present in a single individual, of which particular species are present in most individuals. Approximately 94% of all species in healthy adults belong to the phyla Bacteroidetes (new nomenclature; Bacteroidota), Firmicutes (Bacillota), Actinobacteria (Actinomycetota) or Proteobacteria (Pseudomonadota)^(26,27).

Faecal samples can be collected after bolus transit through the gastrointestinal tract to characterise the gut microbiome. Interindividual variability and plasticity of the gut microbiota composition make identifying a ‘healthy’ microbiome profile challenging, which remains a heavily debated topic⁽²⁸⁾. However, richness and diversity generally provide the gut ecosystem with stability and resilience and are therefore

Abbreviations: BCFA, branched-chain fatty acids; LCD, low-carbohydrate diet; LFD, low-fat diet; LPD, low-protein diet; MS, multiple sclerosis; RCT, randomised controlled trial; SCFA, short-chain fatty acids; T2D, type 2 diabetes.

* Corresponding author: Marjolein P. Schoonakker, email: m.p.schoonakker@lumc.nl



associated with health^(29,30). Richness can be quantified as the total number of bacterial species in a sample; alpha diversity further incorporates relative abundance profiles (microbiota diversity within an individual sample), whilst beta diversity reflects the diversity between samples (inter-variability)⁽³¹⁾. Healthy individuals generally have higher richness and diversity than people with metabolic dysfunction or chronic diseases⁽²⁸⁾. Reduced gut microbiome diversity and richness are associated with a myriad of diseases, including T2D, rheumatoid arthritis, inflammatory bowel disease and several types of cancer⁽³²⁾.

Not only diversity but also the relative abundance (distribution of individual bacterial taxa within a sample) of individual bacterial taxa in the gut may be associated with health or disease⁽³²⁾. Some bacteria are assumed to be primarily health-promoting, such as *Lactobacillus* and *Bifidobacterium*, which are known to produce microbial compounds important for healthy gut function⁽³³⁾. Other bacteria may confer pathogenic effects since their abundance is related to adverse health outcomes⁽³⁴⁾. Several diseases are associated with an alteration in the abundance of specific bacteria. For example, people with T2D have lower faecal numbers of at least one of the genera *Bacteroides*, *Bifidobacterium*, *Roseburia*, *Faecalibacterium* and *Akkermansia* as compared with healthy controls⁽³⁵⁾, whereas colorectal cancer has been associated with an increase in the relative abundance of a core set of twenty-nine bacterial species⁽³⁶⁾.

The complex bacterial ecosystem in the human digestive tract has a myriad of functions, including vitamin synthesis⁽³⁷⁾, provision of colonisation resistance against incoming pathogens⁽³⁴⁾, mediation of immune responses, and digestion of macronutrients into metabolites by the production of a great array of enzymes⁽²⁷⁾. The processing of macronutrients starts in the upper gastrointestinal tract. Carbohydrates are partly digested by salivary amylase, pancreatic enzymes and enzymes on the surface of small intestinal cells and subsequently absorbed by the small intestine wall⁽³⁸⁾. Some carbohydrates are easily digested in the small intestine, while others are more difficult to digest^(38,39). The non-digestible carbohydrates (NDC) thus largely pass through the small intestine into the colon, where they are fermented by the intestinal microbiota. Some NDC are associated with health benefits, such as laxation or lowering of blood cholesterol or glucose levels^(39,40). They are primarily metabolised by the gut microbiome into short-chain fatty acids (SCFA), including acetate, propionate and butyrate⁽²⁶⁾. SCFA are partly consumed by the colonic mucosa and absorbed by intestinal cells, where they confer local effects. Some of the SCFA are partly transported through the basolateral membrane towards the bloodstream and can act on receptors at different body sites. The rest of the SCFA are excreted in the faeces. SCFA appear to regulate hepatic lipid and glucose homeostasis by decreasing glucose output, lipogenesis and free fatty acid accumulation. Also, associations with adipocyte lipolysis and adipogenesis have been reported^(41,42). Moreover, they affect appetite regulation by increasing anorexigenic signalling in appetite centres and affect energy homeostasis through several metabolic pathways activated in parallel^(42–44). Fat can be digested and absorbed in the small intestine after it is

partially emulsified by bile acids and broken down into smaller fragments by pancreatic and intestinal lipases⁽³⁸⁾. A small part of ingested fat is not absorbed in the small intestine and can be metabolised by gut microbiota or excreted^(26,45). The gut microbiome can convert bile acids into secondary bile acids, which are suggested to play a role in epithelial cell integrity, host immune response and gut bacterial composition⁽⁴⁶⁾. Proteins are broken down by gastric, pancreatic and intestinal proteases into smaller protein fragments, tripeptides, dipeptides and individual amino acids, which are partly absorbed by the small intestine⁽³⁸⁾. In the colon, protein fermentation produces diverse metabolites, including SCFA, ammonia, tryptophan metabolites and the branched-chain fatty acids (BCFA) isobutyrate, 2-methylbutyrate and isovalerate^(26,47,48). Tryptophan is a precursor for crucial compounds, including serotonin and kynurenine, which are important for neurobiological functions, gut–brain signalling, gut motility, platelet functions and immune homeostasis⁽⁴⁸⁾. Macronutrient processing thus leads mostly to the absorption of metabolites by the gut, and only a minority of metabolites is excreted in the faeces. These metabolites can be used as an approximate indication for carbohydrate, fat and protein metabolism by the microbiota^(26,49).

Several interventions that would potentially be capable of altering the gut microbiome composition and/or its products to improve health status include the following: (1) supplements of dietary substrates that are selectively utilised by host microorganisms conferring a health benefit (prebiotics); or (2) live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (probiotics); or (3) a mixture comprising live microorganisms and substrate(s) selectively utilised by host microorganisms (synbiotics); or (4) inanimate microorganisms and/or their components (postbiotics); or (5) faecal microbiota transplantations^(33,50). However, diet is the most natural daily modulator of the gut microbiome and health⁽⁵¹⁾. An elaborate modification of the diet may represent an excellent strategy to alter the microbial community composition and function for improved health. However, little is known about the effects of restriction of macronutrient levels on the gut microbiome. Therefore, this review aims to give an overview of the effects of diets restricted in carbohydrates, fat or protein on the bacterial composition of the human gut microbiome and on faecal metabolites.

Methods

Eligibility criteria

The study characteristics were defined as human studies with an intervention described as a low-fat diet (LFD), low-carbohydrate diet (LCD) or low-protein diet (LPD) with gut microbiome as an outcome measure. Studies had to be published in English or with an available English translation. Exclusion criteria included animal studies, paediatric studies, studies with no relevant extractable data or studies with no full text available. The following study designs were included: RCT, non-randomised trials, cohort studies and observational studies. Reviews and case reports were excluded.

Information sources and search strategy

The search strategy (supplementary material) was used to search PubMed, Embase, Web of Science and the Cochrane Library. It was adapted for each dietary intervention (low carbohydrate, low fat and low protein). Articles were selected for screening on 3 June 2021.

Selection and data collection process

Covidence (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia) was used for the screening process. After removing duplicates, the title and abstract screening and subsequent full-text screening were performed with the pre-defined inclusion and exclusion criteria by two independent reviewers (M.S. and N.J. or P.P.). A third review member (H.P.) was available for discussion in case of inconsistencies. Since there is no worldwide-accepted definition of low-fat, low-carbohydrate and low-fat diets, the following definitions were adopted: low-carb, <30 energy% intake of carbohydrates; low-fat, <30 energy% intake of fat; low-protein, <10 energy% intake of protein^(52–54).

Reported data

Outcome domains include changes in alpha diversity, relative bacterial abundance and/or metabolites between baseline and after intervention. Outcome data are reported as either increased or decreased only when a significant difference from baseline was observed. Data are included in the results section only when reported in at least three independent studies to enhance the reliability of our conclusions. Tables with all outcome data are included in the supplementary file. Furthermore, the macronutrient composition of the dietary intervention, participant characteristics (including age, BMI, gender and eventual disease), number of participants, intervention time, wash-out period in case of cross-over, and time of analyses (directly after intervention or at a later moment) were extracted and are reported in tables 1–6.

Quality assessment

The Cochrane Collaboration risk of bias tool was used to assess the methodological quality of the included studies on outcome level. The ROBINS-I tool⁽⁵⁵⁾ was used for non-randomised studies, and the RoB 2.0 tool was used for randomised studies. The risk of bias was independently reviewed by two reviewers (M.P. and N.J. or P.P.) and discussed until a consensus was reached. A third reviewer (H.P.) was available for consultation when consensus was not reached.

Results

Study selection

The literature search resulted in 1178 articles (Supplementary Figure 1). After removing 100 duplicates, 1078 articles were screened on title and abstract. A total of 938 articles were deemed irrelevant to the research question and were excluded, for example, due to the inclusion of animals or lack of gut

microbiome outcomes. Four reports could not be retrieved. Full-text screening on eligibility was conducted on the remaining 136 articles, of which 100 were excluded, resulting in the inclusion of thirty-six articles. Excluded articles often only reported change between intervention groups and did not describe the effect from baseline per individual group. Of the thirty-six included articles, nineteen conducted LCD interventions, twenty conducted LFD interventions and five conducted LPD interventions. Six studies had LCD as well as LFD intervention groups^(56–61), and two had both LCD and LPD intervention groups^(17,62).

Study characteristics

LCD, LFD and LPD study features describe the year of execution, design and patient- and intervention characteristics (Tables 1–3). The LCD studies were published between 2006 and 2021, the LFD studies between 1978 and 2021, and the LPD between 2016 and 2021. Study designs included randomised prospective, randomised cross-over, non-randomised cross-over and non-randomised trials. Some studies used healthy subjects; however, more often, participants with overweight/obesity or specific diseases were included. In the low-carbohydrate studies, participants were often obese. In the low-fat studies, obese persons and persons with multiple sclerosis (MS) were often included. Low-protein studies often examined persons with chronic kidney disease. Study group size differed from six to 246, with most studies including fewer than thirty participants. Not all studies reported the number of subjects in the specific diet groups^(63–66). Some studies use several study groups, which all undergo either LCD, LFD or LPD, where interventions differ in the source of the nutrition or additional supplements^(26,59,67–70). The average age varied between 23.3 and 70.5 years, although the average age was often not reported. Most studies included males and females, while some included only males^(59,63,71–74). The male/female numbers were not always reported. In papers reporting the average BMI, it varied between 21.7 and 35.9 kg/m²; however, most papers reported an average BMI of >25 kg/m² (overweight), and the average BMI was >30 kg/m² (obese) in the majority of studies evaluating the effects of LCD. Intervention time varied substantially between studies, with the shortest intervention time of 2 weeks and the longest of 3 years, while most studies had an intervention time of less than 6 months. In cross-over studies, wash-out time (if reported) varied from zero days to 3 months. In the majority of studies, data collected directly after intervention were used for analysis, except in the studies of Pataky, Russell and Gutierrez-Repiso, where the outcome was measured 3 weeks⁽⁷⁵⁾, 5 weeks⁽⁷³⁾ or 2 months⁽⁵⁷⁾ after the end of the intervention.

Macronutrient composition

The macronutrient composition of the diet was very heterogeneous among the included studies (Tables 4–6). Not all percentages add up to 100%, often without an explanation from the authors. Macronutrient content was sometimes reported in grams, so for this review, the percentage was calculated using the formula 'grams × energy per gram × 100)/consumed kcal/d'. The energy per gram of carbohydrate and protein is 4 kcal (16.7

Table 1. Study characteristics of included low-carbohydrate intervention studies

Author	Year	Set-up	Healthy/diseased	Number analysed in diet group	Male/female	Mean age (years)	Mean BMI (kg/cm ²)	Intervention time	Wash-out period (cross-over)	Timepoint of analysis
Ang ⁽⁷⁴⁾	2020	Cohort	Overweight or obese	17	17/0	NI	NI	4 weeks	–	End of intervention
Basciani ⁽⁶⁷⁾	2020	RP	Obese	16 (per diet group)	19/29	56.2	35.9	6 ½ weeks	–	End of intervention
Brinkworth ⁽⁸²⁾	2009	RP	Obese + ≥1 metabolic risk factor	48	18/30	50.4	33.5	8 weeks	–	End of intervention
Duncan ⁽⁸⁵⁾	2007	RC	Obese	20	20/0	36.7	35.4	1 month	3 days	End of intervention
Duncan ⁽⁷²⁾	2008	NRC	Obese	23	NI	NI	NI	4 weeks	NI	End of intervention
Ferraris ⁽¹⁷⁾	2021	Cohort	DRE	7	NI	NI	NI	1 month	–	End of intervention
Fragiadakis ⁽⁵⁶⁾	2020	RP	Healthy	25	5/19	42.6	32.8	3 months	–	End of intervention
Gutierrez-Repiso ⁽⁵⁷⁾	2019	RP	Obese	9	4/5	38.2	33.1	2 months	–	2 months after end of intervention
Gutierrez-Repiso ⁽⁵⁸⁾	2021	Cohort	Obese	18	8/10	42.6	33.0	2 months	–	End of intervention
Ley ⁽⁸⁶⁾	2006	RP	Obese	NI	NI	NI	NI	1 year	–	End of intervention
Lundsgaard ⁽⁶⁸⁾	2018	RP	Overweight	9	NI	NI	NI	6 weeks	–	End of intervention
Mardinoglu ⁽⁸³⁾	2018	Cohort	NASH	10	8/2	54.0	34.1	2 weeks	–	End of intervention
Murtaza ⁽⁵⁹⁾	2019	NRC	Healthy	10	NI	NI	NI	3 weeks	–	End of intervention
Nagpal ⁽⁶⁰⁾	2019	RC	Healthy or MCI	17	5/12	64.6	NI	6 weeks	6 weeks	End of intervention
O'Keefe ⁽⁶¹⁾	2015	Cohort	Healthy or obese	19	NI	NI	NI	2 weeks	–	End of intervention
Pataky ⁽⁷⁵⁾	2016	NI	Overweight or obese + NAFLD	15	11/4	50.0	34.6	3 weeks	–	3 weeks after end of intervention
Russell ⁽⁷³⁾	2011	RC	Obese	17	17/0	56.4	35.8	4 weeks	None	5 weeks after end of intervention
Swidsinski ⁽⁸⁴⁾	2017	Cohort	MS	NI	NI	NI	NI	6 months	–	End of intervention
Tagliabue ⁽⁶²⁾	2017	Cohort	GLUT 1DS	6	3/3	NI	NI	3 months	–	End of intervention

BMI, body mass index; DRE, drug-resistant epilepsy; GLUT 1DS; glucose transporter 1 deficiency syndrome; MCI, mild cognitive impairment; MS, multiple sclerosis; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NI, not indicated; NRC, non-randomised cross-over; RC, randomised cross-over; RP, randomised parallel.

Table 2. Study characteristics of included low-fat intervention studies

Author	Year	Set-up	Healthy/diseased	Number analysed in intervention group	Men/women	Mean age (years)	Mean BMI (kg/cm ²)	Intervention time	Wash-out period (cross-over)	Timepoint of analysis
Cuevas-Sierra ⁽⁷⁸⁾	2021	RP	Overweight or obese	97	27/70	NI	31.9 (w), 32.1 (m)	4 months	–	End of intervention
Cummings ⁽⁷¹⁾	1978	NRC	Healthy	6	6/0	NI	NI	4 weeks	None	End of intervention
Fava ⁽⁶⁹⁾	2013	RP	Healthy	21 (HC/HGI), 17 (HC/LGI)	43/45	56.0	28.8	24 weeks	–	End of intervention
Fragiadakis ⁽⁵⁶⁾	2020	RP	Healthy	24	5/19	39.2	33.7	3 months	–	End of intervention
Fritsch ⁽²⁰⁾	2021	RC	Ulcerative colitis	17	NI	41.7	27.4	4 weeks	2 weeks	End of intervention
Guevara-Cruz ⁽⁷⁹⁾	2019	RP	Healthy, obese and/or MS	42	NI	NI	NI	2.5 months	–	End of intervention
Gutierrez-Repiso ⁽⁵⁷⁾	2019	RP	Obese	9	4/5	38.2	33.1	2 months	–	2 months after end of intervention
Gutierrez-Repiso ⁽⁵⁸⁾	2021	Cohort	Obese	18	8/10	42.6	33.0	2 months	–	End of intervention
Haro ⁽⁶³⁾	2016	RP	Healthy or MS	NI	198/14	61.2	NI	2 years	–	End of intervention
Haro ⁽⁶⁵⁾	2016	RP	Healthy or MS	NI	20/0	61.4	31.6	1 year	–	End of intervention
Haro ⁽⁶⁴⁾	2017	RP	Healthy or MS	NI	106/0	61.5	30.5	2 years	–	End of intervention
Kahleova ⁽⁸⁷⁾	2020	RP	Overweight	84	15/69	52.9	32.6	16 weeks	–	End of intervention
Liu ⁽¹³⁶⁾	2020	Cohort	Healthy or T2D	16	8/8	50.3	26.4	6 months	–	End of intervention
Murtaza ⁽⁵⁹⁾	2019	Cohort	Healthy	8 (LFD), 10 (LFD per)	21/0	NI	NI	3 weeks	–	End of intervention
Nagpal ⁽⁶⁰⁾	2019	RC	Healthy or MCI	17	5/12	64.6	NI	6 weeks	6 weeks	End of intervention
O'Keefe ⁽⁶¹⁾	2015	Cohort	Healthy or obese	14	NI	NI	NI	2 weeks	–	End of intervention
Ren ⁽⁸⁰⁾	2020	RP	T2D	23	11/12	70.5	NI	12 weeks	–	End of intervention
Santos-Marcos ⁽⁷⁶⁾	2019	RP	Healthy or MS	246	123/123	61.8	31.2	3 years	–	End of intervention
Sugawara ⁽¹³⁷⁾	1992	NRC	Healthy	8	6/2	NI	NI	10 days	30 days	End of intervention
Wan ⁽⁸¹⁾	2019	RP	Healthy	73	35/38	23.3	21.7	6 months	–	End of intervention

BMI, body mass index; DRE, drug-resistant epilepsy; GLUT 1DS, glucose transporter 1 deficiency syndrome; HC, high carbohydrate; HGI, high glycaemic index; MCI, mild cognitive impairment; MS, multiple sclerosis; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NRC, non-randomised cross-over; LFD, low-fat diet; LFD per, low-fat diet periodised; LGI, low glycaemic index; RC, randomised cross-over; RP, randomised parallel; T2D, type 2 diabetes.

Table 3. Study characteristics of included low-protein intervention studies

Author	Year	Set-up	Healthy/ diseased	Number analysed in diet group	Men/women	Mean age (years)	Mean BMI (kg/cm ²)	Intervention time	Wash-out period in (cross-over)	Timepoint of analysis
Di Iorio ⁽⁷⁷⁾	2019	RC	CKD	60	46/14	68.4	26.8	6 months	3 months	End of intervention
Ferraris ⁽¹⁷⁾	2021	Cohort	DRE	7	NI	NI	NI	1 month	-	End of intervention
Lai ⁽⁷⁰⁾	2019	Cohort	CKD	7 (LPD) 9 (LPD + inulin)	NI	NI	NI	6 months	-	End of intervention
Rocchetti ⁽⁶⁶⁾	2021	RC	CKD	NI	NI	NI	NI	6 months	3 months	End of intervention
Tagliabue ⁽⁶²⁾	2017	Cohort	GLUT1 DS	6	3/3	NI	NI	3 months	-	End of intervention

BMI, body mass index; CKD, chronic kidney disease; DRE, drug-resistant epilepsy; GLUT1 DS, glucose transporter 1 deficiency syndrome; NI, not indicated; RC, randomised cross-over; RP, randomised parallel.

kJ) and, per gram of fat, 9 kcal (37.7 kJ). The macronutrient composition of the LCD, LFD, and LPD diets will be described.

In the LCD interventions (Table 4), the carbohydrate content varied between 4% and 25% of total calories, fat content between 14% and 87% of total calories, and protein between 9% and 68% of total calories. The calorie content varied between 600 and 2526 kcal/d; however, only nine out of nineteen papers reported calorie content. In the paper by Gutierrez-Repiso⁽⁵⁷⁾, the number of grams of carbohydrates, fat and protein was only reported for the first 2 months of the intervention, and the number of calories derived from additional vegetables was not reported. The following 2 months of intervention were not specified, although calorie intake was higher than the first 2 months (800–1500 kcal/d). The studies of Basciani⁽⁶⁷⁾ and Lundsgaard⁽⁶⁸⁾ used several study groups; in the trial of Basciani, the protein source differed between groups, and Lundsgaard supplemented either polyunsaturated fatty acids (PUFA) or saturated fatty acids (SFA). Overall, LCD studies were very diverse in regard to dietary composition.

In the LFD interventions (Table 5), the percentage of fat of total calories varied between 8% and 28%. In two studies, the exact fat percentage was not reported, only that it was below 30%^(64,76). Carbohydrate content varied between 13% and 78%. One study examined two study groups consuming the same energy% of carbohydrates, differing in glycaemic index (relative rise in the blood glucose level 2 h after consuming that food)⁽⁶⁹⁾. Protein content varied between 14% and 68% of total calorie intake in studies where the content was indicated. Eight of twenty papers reported the total calorie intake varying between 600 and 2684 kcal/d. Again, LFD interventions were very heterogeneous in macronutrient composition.

The percentage of protein in LPD interventions varied between 3% and 9% of total calories (Table 6). In two out of six papers, the carbohydrate and fat content are not reported^(70,77). The carbohydrate percentage of total calories varied from 4% to 62%, and fat percentages ranged from 32% to 87% of total calories. Furthermore, in two studies, supplementation of keto-analogues was used^(66,77); in another, inulin was supplemented⁽⁷⁰⁾.

Risk of bias

The risk of bias was assessed for randomised (Supplementary Figure 1) and non-randomised (Supplementary Figure 2) studies. Six out of twenty-four randomised trials were judged to be at high risk, thirteen at moderate risk and five at low risk of bias. Studies were classified as being at high risk of bias for different reasons, including not reporting potential cross-over effects in a cross-over trial, deviations from the intended intervention, and missing outcome data. Of the twelve non-randomised trials, four were judged as at high risk, four as at moderate risk and four as at low risk of bias. Most risks of bias were judged as moderate or high due to a lack of reported study procedures, by not mentioning any possible confounders or how confounding factors were controlled for. Blinding of dietary interventions is often not feasible, especially when participants must prepare their food. Therefore, the risk of bias arising from the randomisation process was often judged as moderate.

Table 4. Macro-nutrient composition of low-carbohydrate diets

Author	Year	Carbohydrate (%)	Fat (%)	Protein (%)	Kcal/day	kJ/day	Note
Ang ⁽⁷⁴⁾	2020	5	80	15	NI	NI	3 groups, protein source differed between groups
Basciani ⁽⁶⁷⁾	2020	14	40	46	780	3264	
Brinkworth ⁽⁸²⁾	2009	4	35	61	NI	NI	
Duncan ⁽⁸⁵⁾	2007	4	66	30	NI	NI	
Duncan ⁽⁷²⁾	2008	4	66	30	NI	NI	
Ferraris ⁽¹⁷⁾	2021	4	87	9	1615 (1200-1675)	6757 (5020-7008)	Additional LGI vegetables and supplementation of 250mg DHA in the first 2 months
Fragiadakis ⁽⁵⁶⁾	2020	24	49	26	1485	6213	
Gutierrez-Repiso ⁽⁵⁷⁾	2019	13	23	50	600-800	2510-3347	
Gutierrez-Repiso ⁽⁵⁸⁾	2021	18	14	68	600-800	2510-3347	
Ley ⁽⁸⁶⁾	2006	25	NI	NI	1200-1500 (w); 1500-1800 (m)	5020-6276 (w); 6276-7531 (m)	
Lundsgaard ⁽⁶⁸⁾	2018	20	64	16	NI	NI	2 groups, supplementation of either PUFA or SFAs
Mardinoglu ⁽⁸³⁾	2018	4	72	24	NI	NI	
Murtaza ⁽⁵⁹⁾	2019	4	78	17	NI	NI	
Nagpal ⁽⁶⁰⁾	2019	10	60	30	NI	NI	
O'Keefe ⁽⁶¹⁾	2015	21	52	27	2526	10569	
Pataky ⁽⁷⁵⁾	2016	16	36	47	1059	4430	
Russell ⁽⁷³⁾	2011	5	66	29	NI	NI	
Swidsinski ⁽⁸⁴⁾	2017	11	52	37	NI	NI	
Tagliabue ⁽⁶²⁾	2017	4	87	9	1892	7916	

Overview of macro-nutrient composition demonstrating the percentage of carbohydrate, fat, and protein of every intervention. When percentages were lacking, we calculated the percentage from the number of grams per macro-nutrient with the formula "amount of grams*energy per gram*100/consumed kcal/day".

DHA, docosahexaenoic acid. LGI, low glycemic index. NI, not indicated. PUFA, polyunsaturated fatty acids. SFA: saturated fatty acids.

Table 5. Macro-nutrient composition of low-fat diets

Author	Year	Fat (%)	Carbohydrate (%)	Protein (%)	Kcal/day	kJ/day	Note
Cuevas-Sierra ⁽⁷⁸⁾	2021	22	60	18	NI	NI	2 groups with either high glycemic index or low glycemic index diets
Cummings ⁽⁷¹⁾	1978	21	68	15	2684	11229	
Fava ⁽⁶⁹⁾	2013	28	55	17	NI	NI	
Fragiadakis ⁽⁵⁶⁾	2020	23	53	22	1460	6109	
Fritsch ⁽²⁰⁾	2021	11	64	25	NI	NI	
Guevara-Cruz ⁽⁷⁹⁾	2019	25-35	50-60	15	NI	NI	Additional LGI vegetables and supplementation of 250mg DHA in the first 2 months
Gutierrez-Repiso ⁽⁵⁷⁾	2021	14	18	68	600-800	2510-3347	
Gutierrez-Repiso ⁽⁵⁸⁾	2019	23	13	50	600-800	2510-3347	
Haro ⁽⁶³⁾	2016	28	NI	NI	NI	NI	
Haro ⁽⁶⁵⁾	2016	28	NI	NI	NI	NI	
Haro ⁽⁶⁴⁾	2017	<30	55	15	NI	NI	2 groups, one with a periodized intervention
Kahleova ⁽⁸⁷⁾	2020	8	78	14	1294	5414	
Liu ⁽¹³⁶⁾	2020	25	50-60	15-20	1800-2200	7531-9205	
Murtaza ⁽⁵⁹⁾	2019	20	60	16	NI	NI	
Nagpal ⁽⁶⁰⁾	2019	15	65	20	NI	NI	
O'Keefe ⁽⁶¹⁾	2015	16	70	14	2206	9230	
Ren ⁽⁸⁰⁾	2020	25	59	16	NI	NI	
Santos-Marcos ⁽⁷⁶⁾	2019	<30	NI	NI	NI	NI	
Sugawara ⁽¹³⁷⁾	1992	14	70	16	1823	7627	
Wan ⁽⁸¹⁾	2019	20	66	14	NI	NI	

Overview of macro-nutrient composition demonstrating the percentage of carbohydrate, fat, and protein of every intervention. When percentages were lacking, we calculated the percentage from the number of grams per macro-nutrient with the formula "amount of grams*energy per gram*100/consumed kcal/day".

DHA, docosahexaenoic acid. LGI, low glycemic index. NI, not indicated.

Outcomes

Change in alpha diversity of bacterial gut microbiota. Alpha diversity was reported in seven papers documenting the effects of LCD interventions (Table 7). No difference in alpha diversity

was found after the intervention compared with baseline in all but one study, which examined just a small group of nine participants⁽⁵⁷⁾, where a higher alpha diversity was measured after 2 months of an LCD. Alpha diversity was documented in

Table 6. Macro-nutrient composition of low-protein diets

Author	Year	Protein (%)	Carbohydrate (%)	Fat (%)	Kcal/day	kJ/day	Note
Di Iorio ⁽⁷⁷⁾	2019	9	NI	NI	30-35 kg/day	126-146 kg/day	
Di Iorio ⁽⁷⁷⁾	2019	3	NI	NI	30-35 kg/day	126-146 kg/day	Supplementation of keto-analogues
Ferraris ⁽¹⁷⁾	2021	9	4	87	1615 (1200-1675)	6757 (5020-7008)	
Lai ⁽⁷⁰⁾	2019	7	NI	NI	30-35 kg/day	126-146 kg/day	Supplementation of inulin in one group
Rocchetti ⁽⁶⁶⁾	2021	4	62	32	NI	NI	Supplementation of keto-analogues
Tagliabue ⁽⁶²⁾	2017	9	4	87	1892	7916	

Overview of macro-nutrient composition demonstrating the percentage of carbohydrate, fat, and protein of every intervention. When percentages were lacking, we calculated the percentage from the number of grams per macro-nutrient with the formula "amount of grams*energy per gram*100/consumed kcal/day".
NI, not indicated.

Table 7. Alpha diversity change after dietary intervention compared with baseline

Author	Year	Alpha diversity change	Method of measuring
Low-carbohydrate intervention			
Fragiadakis ⁽⁵⁶⁾	2020	=	Observed number of ASV in a rarefied sample
Gutierrez-Repiso ⁽⁵⁷⁾	2019	↑	Shannon index
Gutierrez-Repiso ⁽⁵⁸⁾	2021	=	Shannon index, Faith's PD, observed ASV and Pielou index
Ley ⁽⁸⁶⁾	2006	=	Shannon index
Lundsgaard ⁽⁶⁸⁾	2018	=	Shannon index
Murtaza ⁽⁵⁹⁾	2019	=	Shannon and Simpson indices
Swidsinski ⁽⁸⁴⁾	2017	=	Percentage of substantial bacterial groups positive in each patient
Low-fat intervention			
Cuevas-Sierra (men) ⁽⁷⁸⁾	2021	↑	Shannon index
Cuevas-Sierra (women) ⁽⁷⁸⁾	2021	=	Shannon index
Fragiadakis ⁽⁵⁶⁾	2020	=	Observed number of ASV in a rarefied sample
Fritsch ⁽²⁰⁾	2021	=	Faith's phylogenetic diversity
Guevara-Cruz ⁽⁷⁹⁾	2019	↑	Shannon index
Gutierrez-Repiso ⁽⁵⁷⁾	2019	↑	Shannon index
Gutierrez-Repiso ⁽⁵⁸⁾	2021	=	Shannon index
Kahleova ⁽⁸⁷⁾	2020	=	Shannon index, Faith's PD, observed ASV and Pielou index
Murtaza ⁽⁵⁹⁾	2019	=	Abundance-weighted PD measure
Ren ⁽⁸⁰⁾	2020	↑	Shannon and Simpson indices
Wan ⁽⁸¹⁾	2019	↑	Faith's phylogenetic diversity
Low-protein intervention			
Rocchetti ⁽⁶⁶⁾	2021	=	Not indicated

↑ significantly higher diversity post-intervention.

= non-significant difference in diversity post-intervention.

eleven LFD intervention groups. Five studies reported increased bacterial diversity^(57,78–81), whereas the other six groups measured no difference in bacterial diversity between baseline and post-intervention. In the study of Cuevas-Sierra⁽⁷⁸⁾, only men displayed an increase in diversity in response to LFD, whereas there was no change in women. Only one paper reported alpha diversity in response to an LPD intervention⁽⁶⁶⁾ and found no difference between baseline and post-intervention. Overall, there is not much evidence that LCD or LPD interventions change alpha diversity, while an increased alpha diversity was measured in response to an LFD in several studies.

Change in the relative abundance of gut bacteria. The relative abundance of various bacterial taxonomic groups changed from baseline to post-intervention in response to the various diets (Supplementary Tables 1–3). However, changes in the abundance of a specific taxonomic group were often reported in just one paper. To provide a more accurate picture of the influence of diet on the relative abundance of bacterial

groups as reliably as currently possible, only the taxa that were reported in at least three intervention groups will be discussed.

Eleven bacterial taxa were reported in three or more different LCD intervention groups (Table 8). These groups are part of five phyla: Actinobacteria, Bacteroidetes, Firmicutes and Verrucomicrobia.

Most studies documented a lower relative abundance of the phylum Actinobacteria in response to an LCD. *Bifidobacterium* was reported in nine study groups, of which seven had a relatively lower abundance in response to an LCD^(59,60,68,72,82–84), while it did not significantly change in the other two^(62,85). Bacteria belonging to the phylum Bacteroidetes were often more abundant after an LCD^(56,58,67,68,74,75,86). A minority of studies documented a decrease in the relative abundance of the genera *Bacteroides*^(73,75). Bacteria belonging to the Firmicutes phylum were generally reported to decrease after an LCD^(58,59,67,72–75,83,85,86). Just the taxonomic sublevels *Lachnospira*^(56,68) and *Streptococcus*⁽⁸³⁾ were reported to increase in some studies. The phylum Proteobacteria and its taxonomic subgroup Enterobacteriaceae were measured in

Table 8. Change in relative abundance of gut bacteria after a low-carbohydrate diet compared with baseline

					Year	Author																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											</
--	--	--	--	--	------	--------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

Pre-postintervention changes in bacterial taxonomic levels that were reported by three or more studies are included in this table

↓ significantly lower abundance post-intervention

↑ significantly higher abundance post-intervention

= no significant difference in abundance post-intervention

response to LCD in six studies, showing no change in relative abundance except for two studies showing an increase^(59,74). The genus *Akkermansia* from phylum Verrucomicrobia was reported in three studies, with one reporting an increase⁽⁵⁹⁾ and the others measuring no difference^(60,84) by use of an LCD.

In summary, the currently available evidence suggests that an LCD impacts the relative bacterial abundance in our gut, inducing an overall decrease of Actinobacteria, an increase of Bacteroidetes and a lower or stable abundance of Firmicutes, while it generally does not appear to affect the relative abundance of Proteobacteria or Verrucomicrobia.

The relative abundance of twenty-three bacterial taxonomic groups was reported in three or more study groups at baseline and after an LFD (Table 9). These twenty-three groups originate from five phyla: Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria and Verrucomicrobia.

The effect of LFD on Actinobacteria and its subtypes varied, as three papers reported no difference in relative abundance^(59,60,87), one paper with two study groups reported an increase⁽⁶⁹⁾ and two papers reported a decrease^(20,56). Bacteroidetes, documented at the phylum level, increased in four study groups^(20,56,64,86) and were not different in another four groups^(64,80,87) after the use of an LFD. Fourteen papers reported change within its taxonomic subgroups in response to LFD, of which four (*Bacteroides*, *Prevotella*, *Parabacteroides* and *P. distasonis*) were reported by a minimum of three papers. The majority reported an increase^(20,56,58,64,69) or no change^(60,64,65,69,71,80,81,87) in relative abundance; none reported a decrease. Changes in abundance of the phylum Firmicutes and its taxonomic members in

response to LFD differed widely. Members of the family of Oscillospiraceae, *Faecalibacterium* and *F. prausnitzii*, showed an overall increase^(20,57,64,65,69,81,87) or no difference^(64,65,69), while its member *Ruminococcus* decreased^(56,80) or showed no difference^(64,65). Many genera (*Lactobacillus*, *Streptococcus*, Lachnospiraceae and its taxonomic members *Roseburia* and *Ruminococcus*) decreased or remained unchanged in response to LFD, while an increase, decrease or no difference in abundance was reported for others, including *Clostridium* and *Dorea* (see Table 9 for references). Likewise, studies documenting the phylum Proteobacteria and its taxonomic unit Enterobacteriaceae yielded a decrease^(57,87) or no difference in abundance^(60,71,87) in response to an LFD compared with baseline. The abundance of the phylum Verrucomicrobia after an LFD was reported in three study groups and did not change in any of them^(59,60,87).

To conclude, current evidence paints a diverse picture of gut bacterial abundance in response to an LFD. Thus, conclusions regarding the impact of an LFD on the gut microbiome are difficult to draw at present, although some trends were observed, including the increase in several Bacteroidetes and its subgroups, a decrease in several Firmicutes subgroups (except for the family Oscillospiraceae and its taxonomic members *Faecalibacterium* and *F. prausnitzii*, which tended to increase), and a tendency of Proteobacteria and subgroups to decrease.

The change in relative gut bacterial abundance in response to an LPD was measured in only two studies (Table 10). One study had two arms using an LPD⁽⁷⁰⁾. Its impact on just two bacteria was reported in at least three study groups. Lactobacillaceae from the phylum Firmicutes decreased in response to an LPD in

Table 9. Change in relative abundance of gut bacteria after a low-fat diet compared with baseline

Phylum	Class	Order	Family	Genus	Species	Author
Actinobacteria (Actinomycetota)	Unspecified					Cummings ⁽⁷¹⁾
	Actinobacteria	Bifidobacteriales	Bifidobacteriaceae	Bifidobacterium	Unspecified	Fava (HGI) ⁽⁶⁹⁾
Bacteroidetes (Bacteroidota)	Unspecified					Fava (LGI) ⁽⁶⁹⁾
	Bacteroidia	Bacteroidales	Bacteroidaceae	Bacteroides	Unspecified	Fragiadakis ⁽⁵⁶⁾
			Prevotellaceae	Prevotella	Unspecified	Fritsch ⁽²⁰⁾
			Tannerellaceae	Parabacteroides	Unspecified	Gutierrez-Repiso ⁽⁵⁷⁾
Firmicutes (Bacillota)	Unspecified					Gutierrez-Repiso ⁽⁵⁸⁾
	Bacilli	Lactobacillales	Lactobacillaceae	Lactobacillus	Unspecified	Haro ⁽⁶⁵⁾
			Streptococcaceae	Streptococcus	Unspecified	Haro (MetS-OB) ⁽⁶⁴⁾
	Clostridia	Eubacteriales	Clostridiaceae	Clostridium	Unspecified	Haro (NonMetS-OB) ⁽⁶⁴⁾
			Lachnospiraceae	Dorea	Unspecified	Haro (NonMetS-non OB) ⁽⁶⁴⁾
			Roseburia	Unspecified		Kahleova ⁽⁶⁷⁾
			Unspecified			Ley ⁽⁸⁶⁾
			Oscillospiraceae	Faecalibacterium	Unspecified	Liu ⁽¹³⁶⁾
			F. prausnitzii	Unspecified		Muraza (non-periodised) ⁽⁵⁹⁾
			Ruminococcus	Unspecified		Muraza (periodised) ⁽⁵⁹⁾
	Proteobacteria (Pseudomonadota)	Unspecified				Nagpal ⁽⁶⁰⁾
Verrucomicrobia (Verrucomicrobiota)	Verrucomicrobiae	Verrucomicrobiales	Akkermansia	Akkermansia	Unspecified	O'Keefe ⁽⁶¹⁾
						Ren ⁽⁶⁰⁾
						Santos-Marcos (women) ⁽⁷⁶⁾
						Santos-Marcos (men) ⁽⁷⁶⁾
						Wang ⁽⁶¹⁾

Pre-postintervention change in bacterial taxonomic levels that were reported by three or more studies are included in this table.

↓ significantly lower abundance post-intervention

↑ significantly higher abundance post-intervention

= no significant difference in abundance post-intervention

HGI: high glycemic index. LGI: low glycemic index. MetS: metabolic syndrome. OB: obese.

three study groups^(70,77), and Enterobacteriaceae from the phylum Proteobacteria decreased in two out of three study groups^(70,77). Thus, the scarcity of data documenting the gut bacterial response to LPD precludes any conclusion as to the effect of such a diet on the gut microbiome.

Change in faecal metabolites. Many metabolites were reported in the included papers (Supplementary Tables 4–6). As with the relative abundance of species, we will only report the metabolites that were documented by at least three trials (or trial groups), which specifically concerned SCFA and lactate. Unfortunately, bile acids and tryptophan/indoles were not reported in three or more papers.

Faecal metabolite concentrations in response to an LCD were documented by seven papers (Table 11). The total SCFA concentration was reported in five of them, all showing a decrease after an LCD compared with baseline^(17,73,82,83,85). Six papers reported faecal acetate, propionate and butyrate concentrations, which consistently decreased in response to an LCD^(17,61,73,82,85). Valerate concentration decreased in two studies^(61,85), while it increased or did not change in one other⁽⁷³⁾, depending on the measured concentration or proportion of SCFA. Isobutyrate was measured in four studies examining the effects of an LCD. Two studies did not find an effect^(74,85), one study demonstrated an increase in both tested study groups⁽⁷³⁾ and one showed a decrease in concentration⁽¹⁷⁾ after the intervention. Faecal isovalerate concentration increased in one study in both study groups⁽⁷³⁾, decreased in one other study⁽⁸⁵⁾

and did not change in yet another study⁽¹⁷⁾. Lactate decreased in one trial⁽⁶¹⁾, with no difference in the two other trials^(73,85).

Faecal metabolites were measured in three studies evaluating the effects of an LFD (Table 12). Acetate increased after an LFD compared with the baseline in two studies^(20,61) and did not change in one other⁽⁶⁹⁾. The quantity of propionate and butyrate increased in one study⁽⁶¹⁾ and did not change compared with the baseline in the two others^(20,69).

Just one study⁽¹⁷⁾ measured metabolites in response to an LPD, so no conclusions can be made concerning the effect of LPD on metabolite concentration.

In concert, the available evidence suggests that faecal SCFA concentrations decline in response to an LCD, while it remains unclear if faecal BCFA concentrations are affected by LCD. An LFD may increase faecal acetate levels. Just one study examined faecal metabolite concentrations in response to LPD, which precludes meaningful conclusions regarding the effects of this dietary intervention.

Discussion

This systematic review summarises current data documenting the impact of dietary macronutrient composition on human gut microbiota. Gut bacteria play a pivotal role in host health through the biosynthesis of vital nutrients such as vitamins, essential amino acids and SCFA⁽⁸⁸⁾. Dietary intake can reproducibly change the human gut microbiome⁽⁸⁹⁾, and knowledge of the impact of dietary interventions on gut

Table 10. Change in relative abundance of gut bacteria after a low-protein diet compared with baseline

Phylum	Class	Order	Family	Genus	Author	Di Iorio ⁽⁷⁷⁾	Lai (no inulin) ⁽⁷⁰⁾	Lai (inulin) ⁽⁷⁰⁾
					Year Species	2019	2019	2019
<i>Firmicutes (Bacillota)</i>	<i>Bacilli</i>	<i>Lactobacillales</i>	<i>Lactobacillaceae</i>	Unspecified		↓	↓	↓
<i>Proteobacteria (Pseudomonadota)</i>	<i>Gammaproteobacteria</i>	<i>Enterobacteriales</i>	<i>Enterobacteriaceae</i>	Unspecified		↓	=	↓

Note: Pre–post-intervention change in bacterial taxonomic levels that were reported by three or more studies are included in this table.

↓ significantly lower abundance post-intervention.

↑ significantly higher abundance post-intervention.

= no significant difference in abundance post-intervention.

Table 11. Change in faecal metabolites after a low-carbohydrate diet compared with baseline

	Author	Ang ⁽⁷⁴⁾	Brinkworth ⁽⁸²⁾		Duncan ⁽⁸⁵⁾		Ferraris ⁽¹⁷⁾	Mardinoglu ⁽⁸³⁾	O'Keefe ⁽⁶¹⁾	Russell ⁽⁷³⁾	
		2020	2009		2007		2021	2018	2015	2011	
		mg/g	mmol/l	mmol/d	mmol/l	Proportion of total SCFA	mg/g	mmol/l	mmol/d	mmol/l	Proportion of total SCFA
SCFA	Total SCFA	=	↓	↓	↓		↓	↓		↓	
	Acetate	=	↓	↓	↓	↑	↓		↓	↓	=
	Butyrate	=	↓	↓	=	↓	↓		↓	↓	↓
	Propionate	=	=	↓	↓	=	↓		↓	↓	=
BCFA	Valerate				↓				↓	=	↑
	Isobutyrate	=			=		↓			↑	↑
	Isovalerate				↓		=			↑	↑
	Lactate				=				↓	=	=

SCFA, short-chain fatty acids; BCFA, branched-chain fatty acids.

↓ significantly lower post-intervention.

↑ significantly higher post-intervention.

= no significant difference post-intervention.

Table 12. Change in faecal metabolites after a low-fat diet compared to baseline

Author		Fava (HGI) ⁽⁶⁹⁾	Fava (LGI) ⁽⁶⁹⁾	Fritsch ⁽²⁰⁾	O'Keefe ⁽⁶¹⁾
Year		2013	2013	2021	2015
Unit of measurement		mmol/l	mmol/l	Relative abundance	mmol/d
SCFA	Acetate	=	=	↑	↑
	Butyrate	=	=	=	↑
	Propionate	=	=	=	↑

SCFA, short-chain fatty acids.

↓ significantly lower post-intervention.

↑ significantly higher post-intervention.

= no significant difference post-intervention.

microbiota composition and metabolic activity is important for understanding their health effects and safety. We summarise available data on the effects of carbohydrate, fat or protein restriction on alpha diversity, the relative abundance of taxonomic units of the major phyla, and faecal metabolites.

Alpha diversity

There is inconclusive evidence to support the notion that the alpha diversity of human gut microbiota is significantly altered by LCD or LPD. In contrast, diets low in fat increased alpha diversity in five out of twelve study groups, while there was no change in response to LFD in the other seven. Low-fat diets are necessarily (relatively) high in carbohydrate and/or protein content, and indigestible carbohydrates (fibres), in particular, are well known to impact gut microbiota⁽⁹⁰⁾. However, the low-fat diets in the studies demonstrating a higher alpha diversity varied widely in macronutrient content, comprising both high or low carbohydrate or protein energy percentage. Therefore, the effect of LFD on alpha diversity cannot (exclusively) be explained by high contents of either (indigestible) carbohydrates or protein, which is in line with a previous review documenting the effects of dietary fibre on the abundance of *Bifidobacterium* and *Lactobacillus* spp. without significant impact on alpha diversity⁽⁹¹⁾. Relatively low microbial alpha diversities have been linked to several acute and chronic disorders^(28,29,92). Thus, the increase in alpha diversity that is generally observed in response to LFD interventions, particularly in people with metabolic disease, may confer health benefits. Notably, four out of five studies demonstrating an increase of alpha diversity in response to an LFD examined overweight or obese participants with or without type 2 diabetes, while only three out of seven showing no effect studied overweight or obese people. Obesity and metabolic disease are well known to be associated with low alpha diversity of the gut microbiome, and low baseline values provide more room for improvement. Thus, the currently available data on the impact of LFD on alpha diversity may well have been confounded by sampling bias.

Relative abundance of taxonomic units

The relative abundance of specific taxonomic units of gut bacteria varies widely between individuals, primarily driven by multiple environmental and lifestyle conditions, and alteration of relative abundance is not necessarily related to health outcomes⁽⁹³⁾. However, the relative abundance (or absence) of

specific bacterial taxonomic units has been observed to relate to human health. Here, we will discuss our findings concerning the potentially relevant changes in relative microbial abundance in response to dietary intervention for taxonomic units per phylum.

Actinobacteria (Actinomycetota). Actinobacteria are one of the four major phyla of the gut microbiota and, even though they represent only a small percentage, are pivotal in maintaining gut homeostasis⁽⁹⁴⁾. *Bifidobacterium* is a genus that, in healthy breastfed infants, dominates the intestine and has much lower but relatively stable levels in adulthood. The different species of *Bifidobacterium* that are present change with age, from childhood to old age⁽⁹⁵⁾. *Bifidobacterium* fulfils important functions in the human gut. Bifidobacterial genera are involved in the protection of the gut mucosal barrier, in the bioavailability of B vitamins, antioxidants, polyphenols and conjugated linoleic acids, and in the production of several short-chain fatty acids⁽⁹⁶⁾. Decreased numbers of *Bifidobacterium* have been associated with a variety of disorders^(96,97), although one study also found high numbers of *Bifidobacterium* in an elderly nursing home population⁽⁹⁸⁾. In seven out of nine included studies examining *Bifidobacterium* abundance, it declined in response to an LCD, which possibly could have unfavourable effects that could counteract the health benefits of carbohydrate restriction. The studies examining the impact of LFD on *Bifidobacterium* abundance produced highly variable results, while there is a lack of data on the effects of LPD on *Bifidobacterium*, precluding any conclusion as to the effects of either LFD or LPD in this context.

Bacteroidetes (Bacteroidota). *Bacteroides* spp., which form ~30% of human gastrointestinal microbiota⁽⁹³⁾, are acknowledged to play a critical role in gut bacterial colonisation and (host) health through their capabilities to metabolise (host) glycans, their role in protein metabolism, deconjugation of bile acids, modulation of immune responsiveness to infections and protection against various auto-immune disorders^(99–105). Because of their broad metabolic potential, the role of the Bacteroidetes in the gastrointestinal microbiota is complex. Reduced abundance of Bacteroidetes and its taxonomic subunit *Bacteroides* have been associated with obesity⁽⁸⁶⁾, inflammatory bowel disease^(106,107) and asthma⁽¹⁰⁸⁾, while increased abundance is associated with type 1 and 2 diabetes⁽¹⁰⁹⁾. The phylum Bacteroidetes and its taxonomic members were typically reported to increase in response to both LCD and LFD interventions included in this review. It has been

speculated that the loss of body weight, which usually accompanies both carbohydrate and fat-restricted dietary interventions, could be responsible for the increase of *Bacteroides* spp. abundance in response to both LCD and LFD⁽⁵⁶⁾, but several studies contradict this argument^(58,78). Recent genomic and proteomic advances have greatly facilitated our understanding of the uniquely adaptive nature of *Bacteroides* species^(110,111). Nevertheless, given the previously mentioned diverse biological features of this phylum, conclusions on health effects from the intervention studies presented here are hampered due to a lack of information.

Firmicutes (Bacillota). A substantial part (~40%) of the human gut microbiome comprises *Firmicutes* spp.⁽⁹³⁾. Members of this phylum generally contribute to host health by being involved in gut permeability, inflammation, glucose metabolism, fatty acid oxidation, synthesis and energy expenditure, partly through the production of butyrate and anti-inflammatory metabolites⁽¹¹²⁾. Indeed, the relative abundance of Firmicutes taxonomic units is decreased in people with several diseases. Faecalibacterium was, for example, decreased in non-alcoholic fatty liver disease, hypertension and gestational diabetes mellitus, and *F. prausnitzii* was decreased in type 2 diabetes, colorectal cancer, coeliac disease, inflammatory bowel disease and several other auto-immune disorders compared to healthy controls^(112,113). The relative abundance of most taxonomic members of the Firmicutes phylum seems to decrease in response to an LCD. The effects of LFD on the relative abundance of Firmicutes vary among taxonomic units of this phylum, with, for example, a decline of *Roseburia* and an increase of *Faecalibacterium* and its species *F. prausnitzii*. As LFD interventions appear to exert mixed effects on the abundance of distinct *Firmicutes* taxonomic units, their potential impact on (gut) health remains unclear.

Metabolites

SCFA produced by gut bacteria play a pivotal role in the gut as well as systemic health^(114,115). Distinct SCFA can be fuel for intestinal epithelial cells, strengthen the gut barrier function, have immunomodulatory functions and improve glucose homeostasis, and may play protective roles against cancer and colitis^(96,116). SCFA are primarily produced by colonic bacteria through anaerobic fermentation of complex carbohydrates that escape digestion and absorption in the small intestine⁽¹¹⁷⁾. Most of the studies reported a reduction of acetate, propionate and butyrate concentrations in faeces in response to an LCD, which is in concordance with literature describing an increase in SCFA by high-carbohydrate interventions^(82,118). However, it should be noted that only SCFA not absorbed by the (healthy) host can be measured in faeces⁽⁴⁹⁾, and these results do not represent all SCFA produced *in vivo*.

LFD are often (relatively) carbohydrate-rich and, therefore, often (but not always) provide plenty of substrates for SCFA production. SCFA levels were indeed increased or stable in the majority of the included studies documenting the impact of LFD on faecal metabolite content. This is in accordance with the decrease in SCFA in high-fat interventions^(82,118). Thus, the fact that SCFA tend to decline in response to LCD calls for careful

consideration of the potential dangers of long-term LCD intervention. In particular, it seems prudent to make sure that the diet provides sufficient fibre (i.e. 25–30 g/d according to the Dietary Guidelines for Americans (<https://www.dietaryguidelines.gov/>) and many other international guidelines) if carbohydrates are restricted for longer periods to sustain adequate SCFA production.

Limitations

A major difficulty in interpreting the results of studies evaluating the effects of an isolated class of macronutrients in our diet concerns the fact that such a component is never consumed alone. Moreover, the considerable variability of compounds within the macronutrient categories can lead to variable effects, even when macronutrient levels are similar. Within the carbohydrate category, literature has demonstrated differential effects on the microbiome when comparing simple and complex carbohydrates^(91,119,120). There is increasing but still limited knowledge of the relationship between the physiochemical structure characteristics and functional properties of non-digestible carbohydrates in the gut microbiome⁽³⁹⁾. Both increases and decreases in fibre content seem to alter the gut microbiota^(91,120,121), and various types of dietary fibre have exhibited functional distinctions in their impact on the composition of human faecal microbiota^(70,119). In the protein category, the source of protein, whether animal or plant based, has also been shown to exert varying effects on the gut microbiome⁽²⁶⁾. Additionally, distinctions emerge when considering the fat content, in which unsaturated versus saturated fats demonstrate differential effects on the gut microbiome⁽¹⁰⁶⁾. Moreover, specific types of polyunsaturated fatty acid or saturated fatty acid^(57,68,122) can have divergent impacts. Furthermore, dietary availability or supplementation of specific compounds in the diet, such as polyphenols^(123,124) and keto-analogues^(66,77), can affect the composition and function of the gut microbiome. Polyphenols are thought to influence carbohydrate metabolism at many levels, including inhibition of carbohydrate digestion⁽¹²⁵⁾, influence fat metabolism via the interaction with bile acids⁽¹²⁶⁾ and affect protein metabolism through the phenolic compounds binding influence to protease activity and protein substrate accessibility⁽¹²⁷⁾. Caloric content varied across studies, influencing the quantity of consumed macronutrients, and very low caloric content could affect the gut microbiome independent of macronutrients⁽¹²⁸⁾. Thus, the type and amount of (other) nutrients and availability of other compounds in each of the specific dietary interventions that were examined in the studies included in this review may have influenced the results. Moreover, the included studies turned out to be very heterogeneous in terms of participant features (healthy or sick, normal weight or obese), age, duration of the interventions and outcome data (highly variable taxa). In this context, it is also pivotal to acknowledge the gut microbial community the macronutrients are introduced into and the microbiota's metabolic potential to utilise such substrates, as the maturity and metabolic potential of the gut microbiome varies throughout life and with health status^(129,130). There is also



accumulating evidence that gut transit time is a key factor in shaping gut microbiota composition and activity, which are linked to human health⁽¹³¹⁾. These factors may have affected the included outcomes and, therefore, complicate drawing uniform conclusions. This review did not differentiate between the methodologies used in relation to collection, fixation, storage, shipping, extraction, library preparation, sequencing and bioinformatic processing. As none of these steps is standardised, the variability created among different studies for each of these steps may cause bias^(132,133), which made risk-of-bias assessment of sample collection and processing of samples challenging. Since there is a lack of access to samples from different sites of the intestine and only faecal samples are available, it is not possible to fully unravel the influence of an intervention on the complete gut microbiome⁽³⁸⁾. Finally, papers often reported only taxonomic units that changed in response to a particular intervention, excluding critical evaluations of unaffected species at the endpoint. Thus, although our review appears to unveil the effects of the restriction of distinct dietary macronutrients despite all these caveats, its results need to be judged in the context of these (partly unavoidable) limitations.

Recommendations for future research

To create a complete overview of the effects of dietary restriction of specific macronutrients on the gut microbiome and its metabolites, it is important to provide a comprehensive and integrated analysis of the microbiome and metabolite changes induced by dietary interventions, where not only taxa and metabolites exhibiting significant change are reported. It is also important to provide detailed information on the diet, including caloric content, the quantity of all macronutrients and the availability of specific compounds such as polyphenols. To enhance the adequacy of the interpretation of data from studies examining the effects of macronutrient restriction, it is important to recognise the potential influence of fibre and caloric content on the gut microbiome. Therefore, researchers could strive to maintain fibre and calorie intake close to what is consumed at baseline, thereby minimising the risk of bias by these dietary characteristics. Participant features should also be described in detail, including health status, and preferably, more extended information should be shared, such as individual transit time. To reduce bias created by the variability in the methodology of sample processing, it could be interesting to obtain raw sequence data for all the studies and then uniformly process them bioinformatically so that at least variation in that step would be removed. Furthermore, 16S rRNA gene amplicon sequencing, which was the most often used technique for microbiota profiling in nutritional studies, is somewhat limited, and the implementation of metagenomics for gut microbial community analysis will allow the generation of in-depth knowledge on the microbial community dynamics as well as the metabolic potential of specific microbial communities^(134,135). Thus, future studies should use integrated advanced metagenomics and metabolomics analyses to foster our understanding of the impact of manipulating dietary macronutrients on gut microbiota and its metabolites.

Conclusions

We have reviewed available studies evaluating the impact of the restriction of distinct dietary macronutrient components on gut microbiota composition. The results, which must be assessed in light of certain limitations, suggest that carbohydrate restriction reduces the abundance of several health-promoting bacterial species as well as the faecal concentration of SCFA. In contrast, low-fat diets appear to have opposite effects on SCFA production and relative abundance of health-promoting bacteria, which is in line with current knowledge on the effect of the fibre content of the diet on the gut microbiome. As to the impact of protein restriction on gut microbiome composition and metabolite production, there are not enough data to draw any conclusions to date.

Supplementary material

The supplementary material for this article can be found at <https://doi.org/10.1017/S0954422424000131>

Acknowledgements

We thank J.W. Schoones for his contribution and guidance in formulating the systematic review search strategy. We thank Nienke A. Jansen for her contribution to title and abstract screening, full-text screening and quality assessment.

Financial support

There was no specific funding for this review, but the salaries of E.B. and M.S. (PhD students) were funded in the context of the FIT (Fasting in diabetes Treatment) trial. The FIT trial was co-funded by Health~Holland, Top Sector Life Sciences & Health and the Dutch Diabetes Foundation. The study funders had no role in the design, analysis or writing of this manuscript.

Competing interests

None.

Authorship

The authors' responsibilities were as follows: M.S., P.P., H.P. and M.N. developed the overall research plan; M.S. devised and executed the literature search; M.S. and N.J. or P.P. performed the title/abstract as well as the full-text screening; M.S. and N.J. or P.P. performed the risk of bias; M.S. was responsible for the construction of data tables and summary and reporting of results; P.P., E.B., H.P., M.N., Q.D. and M.W. reviewed and edited the manuscript; M.S. had primary responsibility for final content; all authors read and approved the final manuscript.

Data sharing

Data described in the manuscript will be made available upon request pending. All proposals requesting data access will need

to specify how the data will be used, and all proposals will need the approval of the trial co-investigator team before the data will be released.

References

- Jayedi A, Ge L, Johnston BC, *et al.* (2023) Comparative effectiveness of single foods and food groups on body weight: a systematic review and network meta-analysis of 152 randomized controlled trials. *Eur J Nutr* **62**, 1153–1164.
- Ge L, Sadeghirad B, Ball GDC, *et al.* (2020) Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. *BMJ* **369**, m696.
- Tobias DK, Chen M, Manson JE, *et al.* (2015) Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* **3**(12), 968–979.
- Johnston BC, Kanters S, Bandayrel K, *et al.* (2014) Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. *JAMA* **312**(9), 923–933.
- Rees K, Takeda A, Martin N, *et al.* (2019) Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2019.
- Xu H, Li X, Adams H, *et al.* (2018) Etiology of metabolic syndrome and dietary intervention. *Int J Mol Sci* **20**, 128.
- Forouhi NG, Misra A, Mohan V, *et al.* (2018) Dietary and nutritional approaches for prevention and management of type 2 diabetes. *BMJ* **361**, k2234.
- Freire R (2020) Scientific evidence of diets for weight loss: different macronutrient composition, intermittent fasting, and popular diets. *Nutrition* **69**, 110549.
- Nield L, Moore H, Hooper L, *et al.* (2007) Dietary advice for treatment of type 2 diabetes mellitus in adults. *Cochrane Database Syst Rev*. 2007.
- Zhang Y, Yang Y, Huang Q, *et al.* (2022) The effectiveness of lifestyle interventions for diabetes remission on patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Worldviews Evid Based Nurs* **20**(1), 64–78.
- Bhatt AA, Choudhary PK, Mahajan RR, *et al.* (2017) Effect of a low-calorie diet on restoration of normoglycemia in obese subjects with type 2 diabetes. *J Endocrinol Metab* **21**(5), 776–780.
- Palmer SC, Maggo JK, Campbell KL, *et al.* (2017) Dietary interventions for adults with chronic kidney disease. *Cochrane Database Syst Rev*. 2017.
- Hanna RM, Ahdoot RS, Rhee CM, *et al.* (2023) New and old approaches to nutritional management of acute and chronic glomerulonephritis. *Curr Opin Nephrol Hypertens* **32**(1), 76–80.
- Naber T, Purohit S (2021) Chronic kidney disease: role of diet for a reduction in the severity of the disease. *Nutrients* **13**(9), 3277.
- Kovesdy CP, Kopple JD, Kalantar-Zadeh K (2013) Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy. *Am J Clin Nutr* **97**(6), 1163–1177.
- Martin-McGill KJ, Bresnahan R, Levy RG, *et al.* (2020) Ketogenic diets for drug-resistant epilepsy. *Cochrane Database Syst Rev*. 2020.
- Ferraris C, Meroni E, Casiraghi MC, *et al.* (2021) One month of classic therapeutic ketogenic diet decreases short chain fatty acids production in epileptic patients. *Front Nutr* **8**, 613100.
- Haridas B, Kossoff EH (2022) Dietary treatments for epilepsy. *Neurol Clin* **40**(4), 785–797.
- Limketkai BN, Iheozor-Ejiro Z, Gjuladin-Hellon T, *et al.* (2019) Dietary interventions for induction and maintenance of remission in inflammatory bowel disease. *Cochrane Database Syst Rev*. 2019.
- Fritsch J, Garces L, Quintero MA, *et al.* (2021) Low-fat, high-fiber diet reduces markers of inflammation and dysbiosis and improves quality of life in patients with ulcerative colitis. *Clin Gastroenterol Hepatol* **19**(6), 1189–1199.e30.
- Lewis JD, Abreu MT (2017) Diet as a trigger or therapy for inflammatory bowel diseases. *Gastroenterology* **152**(2), 398–414.e6.
- Power SE, O'Toole PW, Stanton C, *et al.* (2014) Intestinal microbiota, diet and health. *Br J Nutr* **111**(3), 387–402.
- Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes* **7**(3), 189–200.
- O'Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. *EMBO Rep* **7**(7), 688–693.
- Blaut M, Clavel T (2007) Metabolic diversity of the intestinal microbiota: implications for health and disease. *J Nutr* **137**, 751s–755s.
- Scott KP, Gratz SW, Sheridan PO, *et al.* (2013) The influence of diet on the gut microbiota. *Pharmacol Res* **69**(1), 52–60.
- Thursby E, Juge N (2017) Introduction to the human gut microbiota. *Biochem J* **474**(11), 1823–1836.
- Gentile CL, Weir TL (2018) The gut microbiota at the intersection of diet and human health. *Science* **362**, 776–780.
- Li Z, Zhou J, Liang H, *et al.* (2022) Differences in alpha diversity of gut microbiota in neurological diseases. *Front Neurosci* **16**, 879318.
- McCann KS (2000) The diversity-stability debate. *Nature* **405**, 228–233.
- Claesson MJ, Clooney AG, O'Toole PW (2017) A clinician's guide to microbiome analysis. *Nat Rev Gastroenterol Hepatol* **14**(10), 585–595.
- Hajela N, Ramakrishna BS, Nair GB, *et al.* (2015) Gut microbiome, gut function, and probiotics: implications for health. *J Gastroenterol* **34**(2), 93–107.
- Marco ML (2021) Defining how microorganisms benefit human health. *Microb Biotechnol* **14**(1), 35–40.
- Ducarmen QR, Zwitter RD, Hornung BVH, *et al.* (2019) Gut microbiota and colonization resistance against bacterial enteric infection. *Microbiol Mol Biol Rev* **83**(3), e00007–19.
- Gurung M, Li Z, You H, *et al.* (2020) Role of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine* **51**, 102590.
- Wirbel J, Pyl PT, Kartal E, *et al.* (2019) Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nat Med* **25**(4), 679–689.
- LeBlanc JG, Milani C, de Giori GS, *et al.* (2013) Bacteria as vitamin suppliers to their host: a gut microbiota perspective. *Curr Opin Biotechnol* **24**(2), 160–168.
- Whitney E, Rolfes S, Crowe T, *et al.* (2011) Understanding Nutrition. <https://books.google.nl/books?hl=nl&lr=&id=CJG0DwAAQBAJ&oi=fnd&pg=PP1&dq=Whitney+%26,+Rolfes+S,+Crowe+T,+et+al.+Understanding+nutrition+2011.&ots=m1XbOVb5Ns&sig=KEPhejKIDZj4BNnatYRAWez0tLE#v=onepage&q&f=false> (accessed 10 January 2023).
- Rastall RA, Diez-Munio M, Forssten SD, *et al.* (2022) Structure and function of non-digestible carbohydrates in the gut microbiome. *Benef Microbes* **13**(2), 95–168.
- Holscher HD, Chumpitazi BP, Dahl WJ, *et al.* (2022) Perspective: assessing tolerance to nondigestible carbohydrate consumption. *Adv Nutr* **13**(6), 2084–2097.



41. Hong YH, Nishimura Y, Hishikawa D, *et al.* (2005) Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. *Endocrinology* **146**(12), 5092–5099.
42. Byrne CS, Chambers ES, Morrison DJ, *et al.* (2015) The role of short chain fatty acids in appetite regulation and energy homeostasis. *Int J Obes (Lond)* **39**(9), 1331–1338.
43. den Besten G, Bleeker A, Gerding A, *et al.* (2015) Short-chain fatty acids protect against high-fat diet-induced obesity via a PPAR γ -dependent switch from lipogenesis to fat oxidation. *Diabetes* **64**(7), 2398–2408.
44. Bastings J, Venema K, Blaak EE, *et al.* (2023) Influence of the gut microbiota on satiety signaling. *Trends Endocrinol Metab* **34**(4), 243–255.
45. Hullar MAJ, Fu BC (2014) Diet, the gut microbiome, and epigenetics. *Cancer J* **20**(3), 170–175.
46. Blacher E, Levy M, Tatirovsky E, *et al.* (2017) Microbiome-modulated metabolites at the interface of host immunity. *J Immunol* **198**(2), 572–580.
47. LaBouyer M, Holtrop G, Horgan G, *et al.* (2022) Higher total faecal short-chain fatty acid concentrations correlate with increasing proportions of butyrate and decreasing proportions of branched-chain fatty acids across multiple human studies. *Gut Microbiome* **3**, e2.
48. Agus A, Planchais J, Sokol H (2018) Gut microbiota regulation of tryptophan metabolism in health and disease. *Cell Host Microbe* **23**(6), 716–724.
49. Blaak EE, Canfora EE, Theis S, *et al.* (2020) Short chain fatty acids in human gut and metabolic health. *Benef Microbes* **11**(5), 411–455.
50. Salminen S, Collado MC, Endo A, *et al.* (2021) The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. *Nat Rev Gastroenterol Hepatol* **18**(9), 649–667.
51. Dahl WJ, Rivero Mendoza D, Lambert JM (2020) Diet nutrients and the microbiome. *Prog Mol Biol Transl Sci* **171**, 237–263.
52. Bhandari P, Sapra A (2020) *Low fat diet*. StatPearls. Treasure Island, FL: StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.
53. Wylie-Rosett J, Aebersold K, Conlon B, *et al.* (2013) Health effects of low-carbohydrate diets: where should new research go? *Curr Diab Rep* **13**(2), 271–278.
54. Westerterp-Plantenga MS (2007) How are normal, high- or low-protein diets defined? *Br J Nutr* **97**(2), 217–218.
55. ROBINS-I Tool (2018) Risk of Bias in Non-Randomized Studies - of Interventions. <https://www.riskofbias.info/welcome> (accessed 01 March 2022).
56. Fragiadakis GK, Wastyk HC, Robinson JL, *et al.* (2020) Long-term dietary intervention reveals resilience of the gut microbiota despite changes in diet and weight. *Am J Clin Nutr* **111**(6), 1127–1136.
57. Gutiérrez-Repiso C, Hernández-García C, García-Almeida JM, *et al.* (2019) Effect of synbiotic supplementation in a very-low-calorie ketogenic diet on weight loss achievement and gut microbiota: a randomized controlled pilot study. *Mol Nutr Food Res* **63**(19), e1900167.
58. Gutiérrez-Repiso C, Molina-Vega M, Bernal-López MR, *et al.* (2021) Different weight loss intervention approaches reveal a lack of a common pattern of gut microbiota changes. *J Pers Med* **11**(2), 109.
59. Murtaza N, Burke LM, Vlahovich N, *et al.* (2019) The effects of dietary pattern during intensified training on stool microbiota of elite race walkers. *Nutrients* **11**(2), 261.
60. Nagpal R, Neth BJ, Wang S, *et al.* (2019) Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. *EBioMedicine* **47**, 529–542.
61. O'Keefe SJ, Li JV, Lahti L, *et al.* (2015) Fat, fibre and cancer risk in African Americans and rural Africans. *Nat Commun* **6**, 6342.
62. Tagliabue A, Ferraris C, Uggeri F, *et al.* (2017) Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 deficiency syndrome: a 3-month prospective observational study. *Clin Nutr ESPEN* **17**, 33–37.
63. Haro C, Garcia-Carpintero S, Alcalá-Díaz JF, *et al.* (2016) The gut microbial community in metabolic syndrome patients is modified by diet. *J Nutr Biochem* **27**, 27–31.
64. Haro C, García-Carpintero S, Rangel-Zúñiga OA, *et al.* (2017) Consumption of two healthy dietary patterns restored microbiota dysbiosis in obese patients with metabolic dysfunction. *Mol Nutr Food Res* **61**(12), 1700300.
65. Haro C, Montes-Borrego M, Rangel-Zúñiga OA, *et al.* (2016) Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. *J Clin Endocrinol Metab* **101**(1), 233–242.
66. Rocchetti MT, Di Iorio BR, Vacca M, *et al.* (2021) Ketoanalogs' effects on intestinal microbiota modulation and uremic toxins serum levels in chronic kidney disease (Medika2 Study). *J Clin Med* **10**(4), 840.
67. Basciani S, Camajani E, Contini S, *et al.* (2020) Very-low-calorie ketogenic diets with whey, vegetable, or animal protein in patients with obesity: a randomized pilot study. *J Clin Endocrinol Metab* **105**(9), 2939–2949.
68. Lundsgaard AM, Holm JB, Sjöberg KA, *et al.* (2019) Mechanisms preserving insulin action during high dietary fat intake. *Cell Metab* **29**(1), 50–63.e4.
69. Fava F, Gitau R, Griffin BA, *et al.* (2013) The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. *Int J Obes (Lond)* **37**(2), 216–223.
70. Lai S, Molfino A, Testorio M, *et al.* (2019) Effect of low-protein diet and inulin on microbiota and clinical parameters in patients with chronic kidney disease. *Nutrients* **11**(12), 3006.
71. Cummings JH, Wiggins HS, Jenkins DJ, *et al.* (1978) Influence of diets high and low in animal fat on bowel habit, gastrointestinal transit time, fecal microflora, bile acid, and fat excretion. *J Clin Invest* **61**(4), 953–963.
72. Duncan SH, Lobley GE, Holtrop G, *et al.* (2008) Human colonic microbiota associated with diet, obesity and weight loss. *Int J Obes (Lond)* **32**(11), 1720–1724.
73. Russell WR, Gratz SW, Duncan SH, *et al.* (2011) High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. *Am J Clin Nutr* **93**(5), 1062–1072.
74. Ang QY, Alexander M, Newman JC, *et al.* (2020) Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 Cells. *Cell* **181**(6), 1263–1275.e16.
75. Pataky Z, Genton L, Spahr L, *et al.* (2016) Impact of hypocaloric hyperprotein diet on gut microbiota in overweight or obese patients with nonalcoholic fatty liver disease: a pilot study. *Dig Dis Sci* **61**(9), 2721–2731.
76. Santos-Marcos JA, Haro C, Vega-Rojas A, *et al.* (2019) Sex differences in the gut microbiota as potential determinants of gender predisposition to disease. *Mol Nutr Food Res* **63**(7), e1800870.
77. Di Iorio BR, Rocchetti MT, De Angelis M, *et al.* (2019) Nutritional therapy modulates intestinal microbiota and reduces serum levels of total and free indoxyl sulfate and *p*-cresyl sulfate in chronic kidney disease (Medika Study). *J Clin Med* **8**(9), 1424.

78. Cuevas-Sierra A, Romo-Hualde A, Aranaz P, *et al.* (2021) Diet- and sex-related changes of gut microbiota composition and functional profiles after 4 months of weight loss intervention. *Eur J Nutr* **60**(6), 3279–3301.
79. Guevara-Cruz M, Flores-López AG, Aguilar-López M, *et al.* (2019) Improvement of lipoprotein profile and metabolic endotoxemia by a lifestyle intervention that modifies the gut microbiota in subjects with metabolic syndrome. *J Am Heart Assoc* **8**(17), e012401.
80. Ren M, Zhang H, Qi J, *et al.* (2020) An almond-based low carbohydrate diet improves depression and glycometabolism in patients with type 2 diabetes through modulating gut microbiota and GLP-1: a randomized controlled trial. *Nutrients* **12**(10), 3036.
81. Wan Y, Wang F, Yuan J, *et al.* (2019) Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. *Gut* **68**(8), 1417–1429.
82. Brinkworth GD, Noakes M, Clifton PM, *et al.* (2009) Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations. *Br J Nutr* **101**(10), 1493–1502.
83. Mardinoglu A, Wu H, Bjornson E, *et al.* (2018) An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. *Cell Metab* **27**(3), 559–571.e5.
84. Swidsinski A, Dörffel Y, Loening-Baucke V, *et al.* (2017) Reduced mass and diversity of the colonic microbiome in patients with multiple sclerosis and their improvement with ketogenic diet. *Front Microbiol* **8**, 1141.
85. Duncan SH, Belenguer A, Holtrop G, *et al.* (2007) Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. *Appl Environ Microbiol* **73**(4), 1073–1078.
86. Ley RE, Turnbaugh PJ, Klein S, *et al.* (2006) Microbial ecology: human gut microbes associated with obesity. *Nature* **444**, 1022–1023.
87. Kahleova H, Rembert E, Alwarith J, *et al.* (2020) Effects of a low-fat vegan diet on gut microbiota in overweight individuals and relationships with body weight, body composition, and insulin sensitivity. A randomized clinical trial. *Nutrients* **12**(10), 2917.
88. Bäckhed F, Ley RE, Sonnenburg JL, *et al.* (2005) Host–bacterial mutualism in the human intestine. *Science* **307**, 1915–1920.
89. David LA, Maurice CF, Carmody RN, *et al.* (2014) Diet rapidly and reproducibly alters the human gut microbiome. *Nature* **505**, 559–563.
90. Makki K, Deehan EC, Walter J, *et al.* (2018) The impact of dietary fiber on gut microbiota in host health and disease. *Cell Host Microbe* **23**(6), 705–715.
91. So D, Whelan K, Rossi M, *et al.* (2018) Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. *Am J Clin Nutr* **107**(6), 965–983.
92. Manor O, Dai CL, Kornilov SA, *et al.* (2020) Health and disease markers correlate with gut microbiome composition across thousands of people. *Nat Commun* **11**(1), 5206.
93. Arumugam M, Raes J, Pelletier E, *et al.* (2011) Enterotypes of the human gut microbiome. *Nature* **473**, 174–180.
94. Binda C, Lopetuso LR, Rizzatti G, *et al.* (2018) Actinobacteria: a relevant minority for the maintenance of gut homeostasis. *Dig Liver Dis* **50**(5), 421–428.
95. Arbolea S, Watkins C, Stanton C, *et al.* (2016) Gut bifidobacteria populations in human health and aging. *Front Microbiol* **7**, 1204.
96. Rivi re A, Selak M, Lantin D, *et al.* (2016) Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. *Front Microbiol* **7**, 979.
97. Schwiertz A, Taras D, Sch fer K, *et al.* (2010) Microbiota and SCFA in lean and overweight healthy subjects. *Obesity (Silver Spring)* **18**(1), 190–195.
98. Ducarmon QR, Terveer EM, Nooij S, *et al.* (2021) Microbiota-associated risk factors for asymptomatic gut colonisation with multi-drug-resistant organisms in a Dutch nursing home. *Genome Med* **13**(1), 54.
99. Eribo OA, du Plessis N, Chegou NN (2022) The intestinal commensal, *Bacteroides fragilis*, modulates host responses to viral infection and therapy: lessons for exploration during mycobacterium tuberculosis infection. *Infect Immun* **90**(1), e0032121.
100. Rawat PS, Seyed Hameed AS, Meng X, *et al.* (2022) Utilization of glycosaminoglycans by the human gut microbiota: participating bacteria and their enzymatic machineries. *Gut Microbes* **14**(1), 2068367.
101. Fonseca S, Carvalho AL, Miquel-Clop s A, *et al.* (2022) Extracellular vesicles produced by the human gut commensal bacterium *Bacteroides thetaiotaomicron* elicit anti-inflammatory responses from innate immune cells. *Front Microbiol* **13**, 1050271.
102. Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature* **453**, 620–625.
103. Zafar H, Saier MH Jr (2021) Gut *Bacteroides* species in health and disease. *Gut Microbes* **13**(1), 1–20.
104. Rajili -Stojanovi  M, de Vos WM (2014) The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol Rev* **38**(5), 996–1047.
105. Wexler HM (2007) Bacteroides: the good, the bad, and the nitty-gritty. *Clin Microbiol Rev* **20**(4), 593–621.
106. Singh RK, Chang HW, Yan D, *et al.* (2017) Influence of diet on the gut microbiome and implications for human health. *J Transl Med* **15**(1), 73.
107. Liu S, Zhao W, Lan P, *et al.* (2021) The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. *Protein Cell* **12**(5), 331–345.
108. Wang Q, Li F, Liang B, *et al.* (2018) A metagenome-wide association study of gut microbiota in asthma in UK adults. *BMC Microbiol* **18**(1), 114.
109. Larsen N, Vogensen FK, van den Berg FW, *et al.* (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PLoS One* **5**(2), e9085.
110. Mills RH, Dulai PS, V zquez-Baeza Y, *et al.* (2022) Multi-omics analyses of the ulcerative colitis gut microbiome link *Bacteroides vulgatus* proteases with disease severity. *Nat Microbiol* **7**(2), 262–276.
111. Aggarwal N, Kitano S, Puah GRY, *et al.* (2023) Microbiome and human health: current understanding, engineering, and enabling technologies. *Chem Rev* **123**(1), 31–72.
112. Sun Y, Zhang S, Nie Q, *et al.* (2022) Gut firmicutes: relationship with dietary fiber and role in host homeostasis. *Crit Rev Food Sci Nutr*, **63**(33), 12073–12088.
113. Parsaei M, Sarafraz N, Moaddab SY, *et al.* (2021) The importance of *Faecalibacterium prausnitzii* in human health and diseases. *New Microbes New Infect* **43**, 100928.
114. Nogal A, Valdes AM, Menni C (2021) The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. *Gut Microbes* **13**(1), 1–24.
115. Koh A, De Vadder F, Kovatcheva-Datchary P, *et al.* (2016) From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. *Cell* **165**(6), 1332–1345.



116. Parada Venegas D, De la Fuente MK, Landskron G, *et al.* (2019) Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Front Immunol* **10**, 277.
117. van der Hee B, Wells JM (2021) Microbial regulation of host physiology by short-chain fatty acids. *Trends Microbiol* **29**(8), 700–712.
118. Mueller NT, Zhang M, Juraschek SP, *et al.* (2020) Effects of high-fiber diets enriched with carbohydrate, protein, or unsaturated fat on circulating short chain fatty acids: results from the OmniHeart randomized trial. *Am J Clin Nutr* **111**(3), 545–554.
119. Martínez I, Kim J, Duffy PR, *et al.* (2010) Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. *PLoS One* **5**(11), e15046.
120. Moszak M, Szulińska M, Bogdański P (2020) You are what you eat—the relationship between diet, microbiota, and metabolic disorders—a review. *Nutrients* **12**(4), 1096.
121. Siracusa F, Schaltenberg N, Kumar Y, *et al.* (2023) Short-term dietary changes can result in mucosal and systemic immune depression. *Nat Immunol* **24**(9), 1473–1486.
122. Fu Y, Wang Y, Gao H, *et al.* (2021) Associations among dietary omega-3 polyunsaturated fatty acids, the gut microbiota, and intestinal immunity. *Mediators Inflamm* **2021**, 8879227.
123. Cardona F, Andrés-Lacueva C, Tulipani S, *et al.* (2013) Benefits of polyphenols on gut microbiota and implications in human health. *J Nutr Biochem* **24**(8), 1415–1422.
124. Edwards CA, Havlik J, Cong W, *et al.* (2017) Polyphenols and health: interactions between fibre, plant polyphenols and the gut microbiota. *Nutr Bull* **42**(4), 356–360.
125. Hanhineva K, Törrönen R, Bondia-Pons I, *et al.* (2010) Impact of dietary polyphenols on carbohydrate metabolism. *Int J Mol Sci* **11**(4), 1365–1402.
126. Han Y, Haraguchi T, Iwanaga S, *et al.* (2009) Consumption of some polyphenols reduces fecal deoxycholic acid and lithocholic acid, the secondary bile acids of risk factors of colon cancer. *J Agric Food Chem* **57**(18), 8587–8590.
127. Cirkovic Velickovic TD, Stanic-Vucinic DJ (2018) The role of dietary phenolic compounds in protein digestion and processing technologies to improve their antinutritive properties. *Compr Rev Food Sci Food Saf* **17**(1), 82–103.
128. Ducarmon QR, Grundler F, Le Maho Y, *et al.* (2023) Remodelling of the intestinal ecosystem during caloric restriction and fasting. *Trends Microbiology* **31**(8), 832–844.
129. Ottman N, Smidt H, de Vos WM, *et al.* (2012) The function of our microbiota: who is out there and what do they do? *Front Cell Infect Microbiol* **2**, 104.
130. Turnbaugh PJ, Hamady M, Yatsunenko T, *et al.* (2009) A core gut microbiome in obese and lean twins. *Nature* **457**, 480–484.
131. Procházková N, Falony G, Dragsted LO, *et al.* (2023) Advancing human gut microbiota research by considering gut transit time. *Gut* **72**(1), 180–191.
132. Ducarmon QR, Hornung BVH, Geelen AR, *et al.* (2020) Toward standards in clinical microbiota studies: comparison of three DNA extraction methods and two bioinformatic pipelines. *mSystems* **5**(1), 10–1128.
133. Costea PI, Zeller G, Sunagawa S, *et al.* (2017) Towards standards for human fecal sample processing in metagenomic studies. *Nat Biotechnol* **35**(11), 1069–1076.
134. Livingstone KM, Ramos-Lopez O, Pérusse L, *et al.* (2022) Precision nutrition: a review of current approaches and future endeavors. *Trends Food Sci Technology* **128**, 253–264.
135. Dao MC, Sokolovska N, Brazeilles R, *et al.* (2018) A data integration multi-omics approach to study calorie restriction-induced changes in insulin sensitivity. *Front Physiol* **9**, 1958.
136. Liu C, Shao W, Gao M, *et al.* (2020) Changes in intestinal flora in patients with type 2 diabetes on a low-fat diet during 6 months of follow-up. *Exp Ther Med* **20**(5), 40.
137. Sugawara M, Suzuki K, Endo K, *et al.* (1992) Effect of dietary fat and fiber on fecal flora, bacterial metabolites, and fecal properties in Japanese volunteers. *J Nutr Sci Vitaminol (Tokyo)* **38**(4), 317–328.